Table 5.
Unique number of patients and patient-date pairs after the advanced HNCa diagnosis date (task 18): follow-up data for patients with advanced HNC diagnosis on or after January 1, 2011.
| Variable | Data set A (n=7366) | Data set B (n=7754) | |||||
|
|
Value, n (%) | Unique patient-date pairs, n | Pairs per patient, n | Value, n (%) | Unique patient-date pairs, n | Pairs per patient, n | |
| Diagnosis | 6567 (89.15) | 60,178 | 9.2 | 6893 (88.9) | 370,671 | 53.8 | |
| Drug recordsb | 5840 (79.28) | 113,948 | 19.5 | 6802 (87.72) | 269,225 | 39.6 | |
| Laboratory records | 6860 (93.13) | 179,177 | 26.1 | 6403 (82.58) | 147,314 | 23 | |
| Facility visit | 7269 (98.68) | 274,714 | 37.8 | 6838 (88.19) | 392,175 | 57.4 | |
| Vital sign measurements | 7254 (98.48) | 233,623 | 32.2 | 6123 (78.97) | 217,797 | 35.6 | |
| Nondrug medical procedure | N/Ac | N/A | N/A | 6740 (86.92) | 390,556 | 57.9 | |
| Genomic test | N/A | N/A | N/A | 118 (1.52) | 208 | 1 | |
| Biomarker test | 440 (5.97) | 469 | 1.1 | N/A | N/A | N/A | |
| ECOG PSd | 5416 (73.53) | 100,607 | 17.7 | N/A | N/A | N/A | |
aHNC: head and neck cancer.
bAny drug, not just systemic anticancer therapies.
cN/A: not applicable.
dECOG PS: Eastern Cooperative Oncology group performance status.